Valuation: Decoy Therapeutics Inc.

Market Cap 25.22L 22.19L 20.92L 19.08L 35.69L 24Cr 35.97L 2.51Cr 97.26L 12Cr 94.71L 92.65L 40Cr P/E 2024 *
-
P/E 2025 -0.06x
Enterprise Value -81.87L -72.02L -67.89L -61.94L -1.16Cr -79Cr -1.17Cr -8.15Cr -3.16Cr -40Cr -3.07Cr -3.01Cr -130.16Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
89.57%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Decoy Therapeutics Inc.

1 day-19.22%
1 week+7.61%
Current month+1.97%
1 month-2.81%
3 months-48.17%
6 months-58.37%
Current year-60.05%
1 week 2.18
Extreme 2.18
7.61
1 month 2.18
Extreme 2.18
7.61
Current year 2.18
Extreme 2.18
16.92
1 year 2.18
Extreme 2.18
55.92
3 years 2.18
Extreme 2.18
1,368
5 years 2.18
Extreme 2.18
41,399.97
10 years 2.18
Extreme 2.18
5,33,353.97
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Free

Founder

33,455 5.1062%
31/08/26 Free

Chief Financial Officer

9,682 1.4778%
31/08/26 Free

Director

2,000 0.3053%
Change 5-day change 1-year change 3-year change Capi.($)
-19.22%+7.61%-93.94%-99.70% 25.22L
-3.30%+2.97%+54.99%+104.15% 7.42TCr
-0.12%-1.63%+33.14%+74.86% 5.96TCr
+2.71%-0.84%-16.39%+364.46% 2.58TCr
+0.81%+3.58%+1.01%-5.14% 2.47TCr
-1.05%+2.58%+24.27%-10.32% 2.09TCr
-1.70%-4.15%+147.82%+325.69% 1.53TCr
+2.15%+2.06%+45.57%+169.79% 1.41TCr
-0.43%-5.32%-14.46%+775.94% 1.31TCr
+0.04%-3.00%+15.76%+234.69% 1.19TCr
Average -2.01%+2.60%+19.78%+193.44% 2.6TCr
Weighted average by Cap. -0.71%-0.22%+34.92%+160.29%

Financials

2024 2025
Net sales - -
Net income -55.76L -49.04L -46.23L -42.18L -78.88L -54Cr -79.5L -5.55Cr -2.15Cr -27Cr -2.09Cr -2.05Cr -89Cr -1.25Cr -1.1Cr -1.04Cr -94.7L -1.77Cr -120.17Cr -1.78Cr -12Cr -4.83Cr -61Cr -4.7Cr -4.6Cr -199.02Cr
Net Debt -22.13L -19.46L -18.35L -16.74L -31.3L -21Cr -31.55L -2.2Cr -85.32L -11Cr -83.08L -81.27L -35Cr -1.07Cr -94.2L -88.81L -81.02L -1.52Cr -102.81Cr -1.53Cr -11Cr -4.13Cr -52Cr -4.02Cr -3.93Cr -170.27Cr
Logo Decoy Therapeutics Inc.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Employees
11
Date Price Change Volume
25/26/25 $3.110 -19.22% 13,36,826
23/26/23 $3.850 +24.19% 2,67,72,481
22/26/22 $3.100 +21.09% 10,52,50,192
21/26/21 $2.560 -7.91% 94,274
18/26/18 $2.780 -1.77% 29,324

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCOY Stock